Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCHR1 | Q99705 | 1/20 | 0.35 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.35 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.34 |
| ▸ | CASR | P41180 | 3/20 | 0.33 |
| ▸ | ABL1 | P00519 | 5/20 | 0.33 |
| ▸ | DRD2 | P14416 | 2/20 | 0.33 |
| ▸ | LCK | P06239 | 1/20 | 0.33 |
| ▸ | BCHE | P06276 | 2/20 | 0.32 |
| ▸ | ACHE | P22303 | 2/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | DRD3 | P35462 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL768523 | 0.91 | MCHR1 (0.37) | MCHR1HDAC6CHRM2CASRABL1 | |
| SCHEMBL15061296 | 0.87 | CHRM2 (0.49) | CHRM2 | |
| SCHEMBL768562 | 0.87 | MCHR1 (0.41) | MCHR1HDAC6CHRM2DRD2ACHE | |
| SCHEMBL769174 | 0.86 | MCHR1 (0.41) | MCHR1CHRM2DRD2ACHEDRD3 | |
| SCHEMBL768307 | 0.84 | MCHR1 (0.42) | MCHR1CHRM2DRD2ACHE | |
| SCHEMBL768220 | 0.84 | ACKR3 (0.35) | MCHR1CHRM2DRD2DRD3 | |
| SCHEMBL768850 | 0.82 | CHRM2 (0.41) | MCHR1CHRM2DRD2ACHE | |
| SCHEMBL768753 | 0.82 | MCHR1 (0.42) | MCHR1CHRM2ACHE | |
| SCHEMBL768428 | 0.82 | MCHR1 (0.36) | MCHR1CHRM2DRD2 | |
| SCHEMBL768396 | 0.82 | MCHR1 (0.36) | MCHR1CHRM2DRD2BCHEACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120071467-A1 | AMIDE DERIVATIVE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2012-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120071467-A1 | AMIDE DERIVATIVE | CHRM3, CHRM2, TACR2 | MCHR1 239/4885HDAC6 407/4885CHRM2 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.